Taurus Asset Management LLC Sells 4,500 Shares of Boston Scientific Corporation (BSX)

Taurus Asset Management LLC decreased its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 384,350 shares of the medical equipment provider’s stock after selling 4,500 shares during the period. Boston Scientific makes up about 1.7% of Taurus Asset Management LLC’s holdings, making the stock its 27th largest holding. Taurus Asset Management LLC’s holdings in Boston Scientific were worth $11,211,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of BSX. Swiss National Bank lifted its stake in Boston Scientific by 2.9% during the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after purchasing an additional 156,800 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Boston Scientific by 10.5% during the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after purchasing an additional 867,983 shares during the last quarter. Sit Investment Associates Inc. lifted its stake in Boston Scientific by 37.8% during the third quarter. Sit Investment Associates Inc. now owns 141,710 shares of the medical equipment provider’s stock worth $4,134,000 after purchasing an additional 38,855 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Boston Scientific by 35,016.2% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after purchasing an additional 3,033,800 shares during the last quarter. Finally, Greenwood Capital Associates LLC lifted its stake in Boston Scientific by 71.7% during the third quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock worth $2,671,000 after purchasing an additional 38,249 shares during the last quarter. 90.57% of the stock is owned by institutional investors.

Several equities research analysts have issued reports on BSX shares. Oppenheimer reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Wednesday, August 9th. BidaskClub raised Boston Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, August 19th. Royal Bank Of Canada reissued a “buy” rating and issued a $31.00 target price on shares of Boston Scientific in a research note on Friday, September 1st. Jefferies Group reissued a “hold” rating on shares of Boston Scientific in a research note on Thursday, September 7th. Finally, Stifel Nicolaus reissued a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research note on Monday, September 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the company’s stock. Boston Scientific has a consensus rating of “Buy” and an average target price of $30.97.

Boston Scientific Corporation (BSX) opened at $25.24 on Thursday. The stock has a market capitalization of $34,247.51, a P/E ratio of 20.44, a P/E/G ratio of 1.92 and a beta of 0.96. Boston Scientific Corporation has a 12-month low of $20.36 and a 12-month high of $29.93. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the consensus estimate of $0.31. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.27 EPS. equities analysts anticipate that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.

In other news, insider Valley Gold Master Fund L. Sun acquired 408,006 shares of the firm’s stock in a transaction on Tuesday, November 28th. The stock was acquired at an average price of $0.45 per share, with a total value of $183,602.70. Also, EVP Timothy A. Pratt sold 11,061 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total transaction of $323,423.64. Following the completion of the sale, the executive vice president now directly owns 174,681 shares of the company’s stock, valued at approximately $5,107,672.44. The disclosure for this sale can be found here. Insiders sold a total of 424,698 shares of company stock valued at $12,273,553 over the last 90 days. 0.74% of the stock is currently owned by company insiders.

COPYRIGHT VIOLATION NOTICE: “Taurus Asset Management LLC Sells 4,500 Shares of Boston Scientific Corporation (BSX)” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://ledgergazette.com/2017/12/07/taurus-asset-management-llc-sells-4500-shares-of-boston-scientific-corporation-bsx.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply